$ACAD
ACADIA PHARMACEUTICALS INC

2019 Q4 Form 10-K Financial Statement

#000156459021008372 Filed on February 25, 2021

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2019 Q2
Revenue $98.33M $94.59M $83.21M
YoY Change 65.06% 62.23% 45.81%
Cost Of Revenue $5.300M $2.416M $2.958M
YoY Change 20.45% -37.07% -16.96%
Gross Profit $95.31M $92.17M $80.25M
YoY Change 67.95% 69.22% 49.99%
Gross Profit Margin 96.93% 97.45% 96.44%
Selling, General & Admin $91.90M $72.70M $67.98M
YoY Change 23.69% 18.99% -2.15%
% of Gross Profit 96.43% 78.88% 84.71%
Research & Development $57.50M $62.60M $67.32M
YoY Change 19.29% 17.89% 44.49%
% of Gross Profit 60.33% 67.92% 83.89%
Depreciation & Amortization $640.0K $650.0K $690.0K
YoY Change -17.95% -14.47% -2.82%
% of Gross Profit 0.67% 0.71% 0.86%
Operating Expenses $149.4M $135.3M $135.3M
YoY Change 22.06% 18.48% 16.57%
Operating Profit -$54.09M -$45.42M -$57.09M
YoY Change -17.6% -25.87% -10.91%
Interest Expense $3.300M $2.432M $2.527M
YoY Change 94.12% 97.88% 97.58%
% of Operating Profit
Other Income/Expense, Net $500.0K $747.0K -$12.00K
YoY Change 400.0% -143.43% -94.0%
Pretax Income -$52.60M -$42.24M -$54.58M
YoY Change -19.69% -31.61% -13.44%
Income Tax $400.0K -$264.0K $365.0K
% Of Pretax Income
Net Earnings -$53.04M -$41.98M -$54.94M
YoY Change -19.02% -32.44% -13.16%
Net Earnings / Revenue -53.94% -44.38% -66.03%
Basic Earnings Per Share
Diluted Earnings Per Share -$342.8K -$287.9K -$380.5K
COMMON SHARES
Basic Shares Outstanding 144.5M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q4 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $697.4M $683.8M $381.9M
YoY Change 47.29% 219.38% 48.65%
Cash & Equivalents $189.7M $385.5M $74.43M
Short-Term Investments $507.7M $298.4M $307.5M
Other Short-Term Assets $18.60M $21.40M $18.50M
YoY Change -10.14% 42.67% 44.53%
Inventory $6.341M $4.846M $3.824M
Prepaid Expenses $18.61M $18.51M
Receivables $35.78M $30.80M $31.78M
Other Receivables $2.100M $1.500M $900.0K
Total Short-Term Assets $760.3M $742.3M $436.9M
YoY Change 44.51% 192.13% 45.11%
LONG-TERM ASSETS
Property, Plant & Equipment $3.180M $13.20M $3.427M
YoY Change -3.9% 288.24% 22.39%
Goodwill
YoY Change
Intangibles $2.585M $2.954M $3.323M
YoY Change -36.36% -33.33%
Long-Term Investments
YoY Change
Other Assets $2.857M $2.307M $1.588M
YoY Change 50.45% -48.73% -74.79%
Total Long-Term Assets $22.93M $23.29M $23.94M
YoY Change 62.69% 87.79% 72.25%
TOTAL ASSETS
Total Short-Term Assets $760.3M $742.3M $436.9M
Total Long-Term Assets $22.93M $23.29M $23.94M
Total Assets $783.2M $765.6M $460.9M
YoY Change 44.98% 187.27% 46.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.222M $3.444M $4.650M
YoY Change 128.04% 14.8% 40.91%
Accrued Expenses $67.60M $64.30M $59.16M
YoY Change 19.87% 65.3% 28.9%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $74.83M $67.74M $63.81M
YoY Change 25.62% 62.07% 29.7%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.861M $2.174M $1.413M
YoY Change 83.63% 81.17% 41.3%
Total Long-Term Liabilities $2.861M $2.174M $1.413M
YoY Change 83.63% 81.17% 41.3%
TOTAL LIABILITIES
Total Short-Term Liabilities $74.83M $67.74M $63.81M
Total Long-Term Liabilities $2.861M $2.174M $1.413M
Total Liabilities $84.05M $76.30M $71.97M
YoY Change 37.51% 77.43% 43.36%
SHAREHOLDERS EQUITY
Retained Earnings -$1.704B -$1.651B -$1.609B
YoY Change 16.02%
Common Stock $2.403B $2.340B $1.997B
YoY Change 23.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $699.1M $689.3M $388.9M
YoY Change
Total Liabilities & Shareholders Equity $783.2M $765.6M $460.9M
YoY Change 44.98% 187.27% 46.31%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income -$53.04M -$41.98M -$54.94M
YoY Change -19.02% -32.44% -13.16%
Depreciation, Depletion And Amortization $640.0K $650.0K $690.0K
YoY Change -17.95% -14.47% -2.82%
Cash From Operating Activities -$29.71M -$18.85M -$38.39M
YoY Change -23.98% -55.42% -6.07%
INVESTING ACTIVITIES
Capital Expenditures -$210.0K -$80.00K -$20.00K
YoY Change -63.16% -92.16% -81.82%
Acquisitions
YoY Change
Other Investing Activities -$208.9M $10.00M $10.65M
YoY Change 10.91% -69.51% -378.07%
Cash From Investing Activities -$209.2M $9.920M $10.63M
YoY Change 10.69% -68.79% -369.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $271.5M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 43.06M 320.0M 4.640M
YoY Change -85.68% 152266.67% 57.29%
NET CHANGE
Cash From Operating Activities -29.71M -18.85M -38.39M
Cash From Investing Activities -209.2M 9.920M 10.63M
Cash From Financing Activities 43.06M 320.0M 4.640M
Net Change In Cash -195.8M 311.0M -23.12M
YoY Change -369.77% -3122.74% -44.77%
FREE CASH FLOW
Cash From Operating Activities -$29.71M -$18.85M -$38.39M
Capital Expenditures -$210.0K -$80.00K -$20.00K
Free Cash Flow -$29.50M -$18.77M -$38.37M
YoY Change -23.4% -54.51% -5.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2020 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
CY2019 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
CY2018 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
CY2020 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
CY2019 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
CY2018 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M18D
CY2020 acad Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term1
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm1
P6Y
CY2020 acad Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Remaining Contractual Term1
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm1
P8Y
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccruedLiabilitiesCurrent
CY2019Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccruedLiabilitiesCurrent
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
189680000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
507749000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
35781000
CY2019Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
2093000
CY2019Q4 us-gaap Inventory Net
InventoryNet
6341000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
159637771
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
105967000
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
74826000
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
18606000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
760250000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3180000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
47283000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9524000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1108000
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2585000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4787000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1678000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2857000
CY2020Q4 us-gaap Assets
Assets
782616000
CY2019Q4 us-gaap Assets
Assets
783183000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8493000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7222000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
97474000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
67604000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
44460000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6361000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5180000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2861000
CY2020Q4 us-gaap Liabilities
Liabilities
155607000
CY2019Q4 us-gaap Liabilities
Liabilities
84048000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
159637771
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
155275300
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
155275300
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
16000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
15000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2612663000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2402945000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1985706000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1704122000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
36000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
297000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
627009000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
699135000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
782616000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
783183000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
441755000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
339076000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
223807000
CY2019 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
11344000
CY2018 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
12377000
CY2018 acad License Fees And Royalty Expense
LicenseFeesAndRoyaltyExpense
5953000
CY2020 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
6610000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-997000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
997000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-234383000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-243936000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1256000
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
157331000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-253000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
667000
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
24000
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-8000
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2000
CY2018 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
3000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-281845000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-234590000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-245165000
CY2020 us-gaap Profit Loss
ProfitLoss
-281584000
CY2019 us-gaap Profit Loss
ProfitLoss
-235259000
CY2018 us-gaap Profit Loss
ProfitLoss
-245192000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
81564000
CY2018 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
236000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4055000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5619000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
27569000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
6458000
CY2020 acad Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1769000
CY2020 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
2319000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
84422000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
82265000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1470000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3613000
CY2018 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
578000
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1477000
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1477000
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1476000
CY2020 us-gaap Gain Loss On Investments
GainLossOnInvestments
-997000
CY2019 us-gaap Gain Loss On Investments
GainLossOnInvestments
997000
CY2020 us-gaap Depreciation
Depreciation
1455000
CY2019 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-3000
CY2018 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-88000
CY2020 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
44280000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
12466000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9691000
CY2020 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
-58000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7088000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2121000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
12270000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
15994000
CY2019 acad Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2518000
CY2019 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
1497000
CY2018 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
1367000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-136166000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-151130000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-167470000
CY2020 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
339908000
CY2019 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
578634000
CY2018 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
327914000
CY2020 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
540004000
CY2019 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
413927000
CY2018 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
261678000
CY2018 us-gaap Payments To Acquire Available For Sale Securities Equity
PaymentsToAcquireAvailableForSaleSecuritiesEquity
3149000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7587000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1129000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2104000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
192509000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-165836000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-71489000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
80996000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
371847000
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
306647000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
80996000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
371847000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
306647000
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-8000
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2000
CY2018 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3000
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
27000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
271452000
CY2019 acad Stock Issued During Period Value Stock Options Exercised And Restricted Stock Units Releases
StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleases
95984000
CY2019 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
4411000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-235259000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
82799000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
137331000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
54883000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
67691000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
194467000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
139584000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
71893000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
331798000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
194467000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
139584000
CY2020 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1113000
CY2019 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1597000
CY2018 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1261000
CY2020 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
130000
CY2019 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
34000
CY2018 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
160000
CY2020 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
44280000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
335285000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
298537000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4428000
CY2018 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
3682000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-245192000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
82312000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
669000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
699135000
CY2020 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
44280000
CY2020 acad Stock Issued During Period Value Stock Options Exercised And Restricted Stock Units Releases
StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleases
73834000
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
7162000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-281584000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
84443000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-261000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
627009000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
189680000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4787000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2018Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4826000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4787000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
194467000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</p>
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
189680000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
326028000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
134758000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
331798000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
139584000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
194467000
CY2020 us-gaap Inventory Write Down
InventoryWriteDown
400000
CY2019 us-gaap Inventory Write Down
InventoryWriteDown
1100000
CY2018 us-gaap Inventory Write Down
InventoryWriteDown
2700000
CY2020 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2016Q2 acad Regulatory Milestone Payment
RegulatoryMilestonePayment
8000000.0
CY2016Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
8000000.0
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1500000
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1500000
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1500000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
1100000
CY2020 us-gaap Advertising Expense
AdvertisingExpense
51100000
CY2019 us-gaap Advertising Expense
AdvertisingExpense
38300000
CY2018 us-gaap Advertising Expense
AdvertisingExpense
39800000
CY2019Q4 us-gaap Prepaid Advertising
PrepaidAdvertising
0
CY2020Q4 us-gaap Prepaid Advertising
PrepaidAdvertising
0
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration Risk</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash, cash equivalents, investment securities, accounts receivable, and restricted cash. The Company invests its excess cash primarily in money market funds, U.S. treasury notes, and high quality, marketable debt instruments of corporations and government sponsored enterprises in accordance with the Company’s investment policy. The Company’s investment policy defines allowable investments and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity. All investment securities have a credit rating of at least A3/A- or better, or P-1/A-1 or better, as determined by Moody’s Investors Service or Standard &amp; Poor’s. Further, the Company specifies credit quality standards for its customers that are designed to limit the Company’s credit exposure to any single party.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company does not currently have any of its own manufacturing facilities, and therefore it depends on an outsourced manufacturing strategy for the production of NUPLAZID for commercial use and for the production of its product candidates for clinical trials. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has contracts in place with two third-party manufacturers of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercial </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">drug product and one third-party manufacturer of drug substance that is approved for the production of NUPLAZID active pharmaceutical ingredient (API). </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although there are potential sources of supply other than the Company’s existing suppliers, any new supplier would be required to qualify under applicable regulatory requirements.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into distribution agreements with a limited number of SPs and SDs, and all of the Company’s product sales are to these customers. For the year ended December 31, 2020, the Company’s four largest customers represented approximately 74% of the Company’s product revenue and 75% of the Company’s accounts receivable balance at December 31, 2020. For the year ended December 31, 2019, the Company’s four largest customers represented approximately 77% of the Company’s product revenue and 75% of the Company’s accounts receivable balance at December 31, 2019. For the year ended December 31, 2018, the Company’s four largest customers represented approximately 85% of the Company’s product revenue and 84% of the Company’s accounts receivable balance at December 31, 2018.</p>
CY2019 acad Number Of Large Customers
NumberOfLargeCustomers
4
CY2018 acad Number Of Large Customers
NumberOfLargeCustomers
4
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
82265000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
81564000
CY2020Q4 us-gaap Equity Securities Fv Ni Cost
EquitySecuritiesFvNiCost
305899000
CY2020Q4 acad Equity Securities Fv Ni Unrealized Gains
EquitySecuritiesFvNiUnrealizedGains
74000
CY2020Q4 acad Equity Securities Fv Ni Unrealized Losses
EquitySecuritiesFvNiUnrealizedLosses
43000
CY2020Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
305930000
CY2019Q4 acad Debt Securities And Equity Securities Fv Ni Amortized Cost
DebtSecuritiesAndEquitySecuritiesFvNiAmortizedCost
507465000
CY2019Q4 acad Debt Securities And Equity Securities Fv Ni Unrealized Gains
DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedGains
335000
CY2019Q4 acad Debt Securities And Equity Securities Fv Ni Unrealized Losses
DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedLosses
51000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19516000
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20824000
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019Q4 acad Debt Securities And Equity Securities Fv Ni
DebtSecuritiesAndEquitySecuritiesFvNi
507749000
CY2020 acad Available For Sale Investment Securities Contractual Maturity Dates
AvailableForSaleInvestmentSecuritiesContractualMaturityDates
less than one year
CY2019Q4 acad Available For Sale Securities Debt Maturities Rolling Year One Through Two
AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwo
24300000
CY2020Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
24
CY2019Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
20
CY2020Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
169353000
CY2020Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
43000
CY2020Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
169353000
CY2020Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
43000
CY2019Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
220834000
CY2019Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
51000
CY2019Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
220834000
CY2019Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
51000
CY2020Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
632576000
CY2019Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
623123000
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1453000
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3175000
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
6367000
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1685000
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1862000
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1481000
CY2020Q4 us-gaap Inventory Net
InventoryNet
9682000
CY2019Q4 us-gaap Inventory Net
InventoryNet
6341000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13109000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8512000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3948000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5332000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9161000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3180000
CY2020 us-gaap Depreciation
Depreciation
1500000
CY2019 us-gaap Depreciation
Depreciation
1300000
CY2018 us-gaap Depreciation
Depreciation
1500000
CY2020 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
3100000
CY2019 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
200000
CY2018 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
1600000
CY2019Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
1971000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2661000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1829000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
97474000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
67604000
CY2019Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
271500000
CY2019Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7187500
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
17427228
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
28.69
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1937006
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
43.78
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2571633
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
28.71
CY2020Q4 acad Accrued Clinical Development Services Current
AccruedClinicalDevelopmentServicesCurrent
28380000
CY2019Q4 acad Accrued Clinical Development Services Current
AccruedClinicalDevelopmentServicesCurrent
14273000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
25811000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
21080000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
18969000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
13691000
CY2020Q4 acad Accrued Sales Allowances Current
AccruedSalesAllowancesCurrent
14115000
CY2019Q4 acad Accrued Sales Allowances Current
AccruedSalesAllowancesCurrent
11326000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5087000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3434000
CY2020Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
2451000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
350607
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
31.75
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
16441994
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
30.40
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
379233000
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
9691855
CY2020Q4 acad Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice
29.71
CY2020Q4 acad Share Based Compensation Arrangement By Share Based Payment Award Options Vested Intrinsic Value1
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue1
230156000
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
6750139
CY2020Q4 acad Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOutstandingWeightedAverageExercisePrice
31.38
CY2020Q4 acad Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Intrinsic Value1
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValue1
149078000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
9691855
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
29.71
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
230156000
CY2020 acad Closing Market Price Of Common Stock
ClosingMarketPriceOfCommonStock
53.46
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
55500000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
56600000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
11200000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
73800000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
24.16
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
15.97
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
12.14
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
99100000
CY2020 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
PSUs for which the number of shares issuable at the end of performance period can reach up to 200% of the shares approved in the award based on the achievement of certain pre-defined Acadia-specific performance criteria and continued employment through the vesting period
CY2020 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.60
CY2020 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1
CY2020 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.05
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
5100000
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
4300000
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
3600000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-238885000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-123411000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-78112000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-42088000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-110972000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-165824000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-280973000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-234383000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-243936000
CY2020 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
400000
CY2019 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
900000
CY2018 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
1300000
CY2020 acad Income Tax Expense Permanent Tax Differences
IncomeTaxExpensePermanentTaxDifferences
991000
CY2020 us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
200000
CY2020Q4 acad Federal Research And Development Credit Carryforwards
FederalResearchAndDevelopmentCreditCarryforwards
55500000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
218905000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
182948000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
63886000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
48069000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
47547000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
45440000
CY2020Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
28470000
CY2019Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
18303000
CY2020Q4 acad Deferred Tax Assets Lease Obligations
DeferredTaxAssetsLeaseObligations
11675000
CY2019Q4 acad Deferred Tax Assets Lease Obligations
DeferredTaxAssetsLeaseObligations
2366000
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
7109000
CY2019Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
59783000
CY2020Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
6073000
CY2019Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
7607000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
9390000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
8773000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
393055000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
373289000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
380533000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
370783000
CY2020Q4 acad Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
11142000
CY2019Q4 acad Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
2301000
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
1380000
CY2019Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
205000
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
12522000
CY2019Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
2506000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
9800000
CY2017 acad Limitation On Utilization Of No Ls Percentage
LimitationOnUtilizationOfNOLsPercentage
0.80
CY2019Q4 acad Deferred Tax Asset Switzerland Tax Reform
DeferredTaxAssetSwitzerlandTaxReform
57000000.0
CY2020Q4 acad Deferred Tax Asset Switzerland Tax Reform
DeferredTaxAssetSwitzerlandTaxReform
52800000
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-59004000
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-49365000
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-51226000
CY2019 acad Income Tax Expense Permanent Tax Differences
IncomeTaxExpensePermanentTaxDifferences
5691000
CY2018 acad Income Tax Expense Permanent Tax Differences
IncomeTaxExpensePermanentTaxDifferences
3379000
CY2020 acad Income Tax Expenses Write Off Of Iprd
IncomeTaxExpensesWriteOffOfIPRD
9565000
CY2020 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
17909000
CY2019 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
16687000
CY2018 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
7941000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
5925000
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
99846000
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
34333000
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-5038000
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2138000
CY2018 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1017000
CY2020 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
2665000
CY2019 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
1861000
CY2018 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
2938000
CY2020 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
4208000
CY2019 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
20413000
CY2018 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
20896000
CY2020 acad Income Tax Reconciliation Limitation On Executive Compensation
IncomeTaxReconciliationLimitationOnExecutiveCompensation
3705000
CY2019 acad Income Tax Reconciliation Limitation On Executive Compensation
IncomeTaxReconciliationLimitationOnExecutiveCompensation
1178000
CY2018 acad Income Tax Reconciliation Limitation On Executive Compensation
IncomeTaxReconciliationLimitationOnExecutiveCompensation
53000
CY2020 acad Income Tax Reconciliation Deferred Rate Adjustment
IncomeTaxReconciliationDeferredRateAdjustment
2130000
CY2020 acad Income Tax Reconciliation Switzerland Tax Reform
IncomeTaxReconciliationSwitzerlandTaxReform
53045000
CY2019 acad Income Tax Reconciliation Switzerland Tax Reform
IncomeTaxReconciliationSwitzerlandTaxReform
-59181000
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
328000
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-742000
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-159000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
611000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
876000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1256000
CY2020 acad Unrecognized Tax Benefits Increases Resulting From Current And Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentAndPriorPeriodTaxPositions
2900000
CY2019 acad Unrecognized Tax Benefits Increases Resulting From Current And Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentAndPriorPeriodTaxPositions
1900000
CY2018 acad Unrecognized Tax Benefits Increases Resulting From Current And Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentAndPriorPeriodTaxPositions
3100000
CY2019Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2020 us-gaap Income Tax Examination Penalties Expense
IncomeTaxExaminationPenaltiesExpense
0
CY2019 us-gaap Income Tax Examination Penalties Expense
IncomeTaxExaminationPenaltiesExpense
0
CY2018 us-gaap Income Tax Examination Penalties Expense
IncomeTaxExaminationPenaltiesExpense
0
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
6945000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5037000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1933000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2722000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1908000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
3104000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
212000
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
36000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9843000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
6945000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5037000
CY2020 acad Lease Expiration Month And Year
LeaseExpirationMonthAndYear
2031-02
CY2020 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
The Company leases facilities and certain equipment under noncancelable operating leases with remaining lease terms of 1.0 year to 10.4 years, some of which include options to extend the lease for up to two five-year terms.
CY2020 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
some of which include options to extend the lease for up to two five-year terms.
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
29762000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
61193000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6361000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
49547000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
9795000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
6917000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
5155000
CY2018 us-gaap Operating Lease Cost
OperatingLeaseCost
4503000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
4480000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
4841000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
42039000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
13399000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5087000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3434000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
44460000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5284000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
7193000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6635000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
6397000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
5922000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
11646000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
49547000
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y4M24D
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.047
CY2020Q3 acad Capitalization Of Right Of Use Asset
CapitalizationOfRightOfUseAsset
40300000
CY2020Q3 acad Capitalization Of Lease Liability
CapitalizationOfLeaseLiability
40300000
CY2020Q1 us-gaap Revenues
Revenues
90068000
CY2020Q2 us-gaap Revenues
Revenues
110103000
CY2020Q3 us-gaap Revenues
Revenues
120577000
CY2020Q4 us-gaap Revenues
Revenues
121007000
CY2020 us-gaap Revenues
Revenues
441755000
CY2020Q1 us-gaap Gross Profit
GrossProfit
87269000
CY2020Q2 us-gaap Gross Profit
GrossProfit
107204000
CY2020Q3 us-gaap Gross Profit
GrossProfit
118572000
CY2020Q4 us-gaap Gross Profit
GrossProfit
118499000
CY2020 us-gaap Gross Profit
GrossProfit
431544000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-88023000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-42141000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-84660000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-66760000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-281584000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.57
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2020Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.42
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.79
CY2019Q1 us-gaap Revenues
Revenues
62959000
CY2019Q2 us-gaap Revenues
Revenues
83205000
CY2019Q3 us-gaap Revenues
Revenues
94586000
CY2019Q4 us-gaap Revenues
Revenues
98326000
CY2019 us-gaap Revenues
Revenues
339076000
CY2019Q1 us-gaap Gross Profit
GrossProfit
60009000
CY2019Q2 us-gaap Gross Profit
GrossProfit
80247000
CY2019Q3 us-gaap Gross Profit
GrossProfit
92170000
CY2019Q4 us-gaap Gross Profit
GrossProfit
95306000
CY2019 us-gaap Gross Profit
GrossProfit
327732000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-85304000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-54941000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-41978000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-53036000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-235259000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.60

Files In Submission

Name View Source Status
0001564590-21-008372-index-headers.html Edgar Link pending
0001564590-21-008372-index.html Edgar Link pending
0001564590-21-008372.txt Edgar Link pending
0001564590-21-008372-xbrl.zip Edgar Link pending
acad-10k_20201231.htm Edgar Link pending
acad-10k_20201231_htm.xml Edgar Link completed
acad-20201231.xsd Edgar Link pending
acad-20201231_cal.xml Edgar Link unprocessable
acad-20201231_def.xml Edgar Link unprocessable
acad-20201231_lab.xml Edgar Link unprocessable
acad-20201231_pre.xml Edgar Link unprocessable
acad-ex1011_411.htm Edgar Link pending
acad-ex211_12.htm Edgar Link pending
acad-ex231_7.htm Edgar Link pending
acad-ex311_11.htm Edgar Link pending
acad-ex312_8.htm Edgar Link pending
acad-ex321_10.htm Edgar Link pending
acad-ex322_9.htm Edgar Link pending
acad-ex32_633.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gpmwmhg00msf000001.jpg Edgar Link pending
gpmwmhg00msf000002.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending